Chimerix
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
$768.05M
-8.7
-1.00
$212K
79
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 79 full-time employees. The Company’s advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. The company is conducting phase I dose escalation studies of ONC206 to evaluate safety and PK data. The second-generation imipridone (ONC206) is in dose-escalating clinical trials for adult and pediatric patients with primary central nervous system tumors. Its other product candidates include ONC212 and CMX521. ONC212 is an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. CMX521 is a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. CMX521 is not mutagenic, clastogenic, or associated with mitochondrial toxicity. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides. This library includes approximately 3,500 nucleoside analog compounds. The company is a wholly owned subsidiary of Jazz Pharmaceuticals plc.
emptyResult
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Durham, North Carolina and currently employs 79 full-time employees. The Company’s advanced clinical-stage development program, dordaviprone (ONC201), is in development for H3 K27M-mutant glioma. The company is conducting phase I dose escalation studies of ONC206 to evaluate safety and PK data. The second-generation imipridone (ONC206) is in dose-escalating clinical trials for adult and pediatric patients with primary central nervous system tumors. Its other product candidates include ONC212 and CMX521. ONC212 is an imipridone, investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. CMX521 is a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. CMX521 is not mutagenic, clastogenic, or associated with mitochondrial toxicity. The Chimerix Chemical Library contains over 10,000 heterocyclic ring systems and nucleosides. This library includes approximately 3,500 nucleoside analog compounds. The company is a wholly owned subsidiary of Jazz Pharmaceuticals plc.
Recently from Cashu
Jazz Pharmaceuticals Acquires Chimerix to Enhance Oncology Pipeline with Dordaviprone
Jazz Pharmaceuticals Strengthens Oncology Pipeline Through Chimerix Acquisition In a significant move to bolster its oncology portfolio, Jazz Pharmaceuticals plc has finalized its acquisition of Chime…
Jazz Pharmaceuticals Acquires Chimerix to Enhance Oncology Pipeline with Dordaviprone
Jazz Pharmaceuticals Expands Oncology Pipeline with Chimerix Acquisition Jazz Pharmaceuticals plc successfully completes its acquisition of Chimerix, Inc. for approximately $935 million, effectively i…